Skip to main content

Advertisement

Table 3 Frequent adverse events (> 1.0%)

From: Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

Type of event Treatment cycles N = 1851 Maximum number of repetitions
  N %
Pain at the administration site 402 21.7 24
Shivering 368 19.9 23
Burning sensation at the administration site 297 16.0 17
Chills 171 9.2 16
Local infection 70 3.8 4
Fever 42 2.3 7
Ulcer worsening* 30 1.6 2
Vomits 25 1.4 10
  1. *:Reported by the doctors as adverse events. In fact, worsening of the ulcer as a therapeutic failure occurred in 209 cycles (11.3%).